Genesis Global Group
PharmOptima
GD3

You will now be redirected to the GD3 website

PharmOptima is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.

Learn more about GD3
Search

News

Visit GD3 at booth 1517 at the SOT 63rd Annual Meeting and ToxExpo Mar 10-14 in Salt Lake City, UT #1517

  • May 10, 2023

    Genesis Drug Discovery & Development (GD3), a member of Genesis Global Group, acquires JSS Medical Research to expand its clinical services portfolio.

    Read More
  • January 10, 2023

    Genesis Axis Acquires Organochem to Grow the Preclinical Chemistry Services Portfolio.

    Read More
  • October 7, 2021

    Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)

    Read More
  • March 4, 2021

    Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add “off the shelf” PK profiling capabilities to its portfolio

    Read More
  • January 6, 2021

    Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services

    Read More
  • December 9, 2020

    Genesis Biotechnology Group announces second year of CRO relationship with Yale University

    Read More
  • September 16, 2020

    Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development

    Read More
  • September 16, 2020

    Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer

    Read More
  • September 16, 2020

    Genesis Biotechnology Group Appoints Erich E. Dagnal as Director of Mergers & Acquisitions

    Read More
  • August 5, 2020

    Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services

    Read More
  • August 4, 2020

    Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima

    Read More
  • November 19, 2019

    Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development (GD3)

    Read More
  • September 24, 2019

    Genesis Biotechnology Group® (GBG) Announces First Annual Community Fall Fest in Hamilton

    Read More
  • June 18, 2019

    Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma

    Read More
  • February 27, 2019

    Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.

    Read More
  • October 30, 2018

    Genesis Biotechnology Group announces partnership with Yale University

    Read More
  • July 19, 2018

    Genesis Drug Discovery & Development Appoints Olesia Buiakova, M.D., Ph.D., as Chief Scientific Officer

    Read More
  • April 29, 2018

    Abstract accepted for Presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting April 29 - May 03, 2018 in Honolulu, Hawaii

    Read More
  • March 1, 2017

    Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima

    Read More